DK1203770T3 - Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme - Google Patents

Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme

Info

Publication number
DK1203770T3
DK1203770T3 DK02002073T DK02002073T DK1203770T3 DK 1203770 T3 DK1203770 T3 DK 1203770T3 DK 02002073 T DK02002073 T DK 02002073T DK 02002073 T DK02002073 T DK 02002073T DK 1203770 T3 DK1203770 T3 DK 1203770T3
Authority
DK
Denmark
Prior art keywords
ones
hyperplasia
pyran
dihydropyran
diseases
Prior art date
Application number
DK02002073T
Other languages
English (en)
Inventor
Suvit Thaisrivongs
Chih-Ping Yang
Joseph Walter Strohbach
Stephen Ronald Turner
Donna Lee Romero
Louis L Skaletzki
Paul Adrian Aristoff
Ronald B Gammill
Paul D Johnson
Harvey Irving Skulnick
Richard C Piper
Ruben A Tommasi
Qingwei Zhang
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of DK1203770T3 publication Critical patent/DK1203770T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
DK02002073T 1992-11-13 1993-11-09 Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme DK1203770T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97534392A 1992-11-13 1992-11-13
US9087693A 1993-07-13 1993-07-13
US13064193A 1993-10-01 1993-10-01
EP94900546A EP0668860B1 (en) 1992-11-13 1993-11-09 Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses
PCT/US1993/010645 WO1994011361A1 (en) 1992-11-13 1993-11-09 Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses

Publications (1)

Publication Number Publication Date
DK1203770T3 true DK1203770T3 (da) 2005-05-23

Family

ID=27376682

Family Applications (2)

Application Number Title Priority Date Filing Date
DK94900546T DK0668860T3 (da) 1992-11-13 1993-11-09 Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af HIV og andre retroviruser
DK02002073T DK1203770T3 (da) 1992-11-13 1993-11-09 Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK94900546T DK0668860T3 (da) 1992-11-13 1993-11-09 Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af HIV og andre retroviruser

Country Status (26)

Country Link
EP (2) EP1203770B1 (da)
JP (1) JP3583127B2 (da)
KR (1) KR100314975B1 (da)
CN (1) CN1040321C (da)
AT (2) ATE290531T1 (da)
AU (1) AU687368B2 (da)
BR (1) BR9307451A (da)
CA (1) CA2145661C (da)
CZ (1) CZ291853B6 (da)
DE (2) DE69332292T2 (da)
DK (2) DK0668860T3 (da)
ES (2) ES2237624T3 (da)
FI (1) FI120399B (da)
GE (1) GEP20094660B (da)
HU (1) HU228126B1 (da)
IL (1) IL107556A (da)
LV (1) LV13088B (da)
MY (1) MY119031A (da)
NO (1) NO319914B1 (da)
NZ (1) NZ258013A (da)
PL (1) PL178653B1 (da)
PT (2) PT668860E (da)
RU (1) RU2134691C1 (da)
SK (1) SK285001B6 (da)
WO (1) WO1994011361A1 (da)
ZA (1) ZA938019B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0720607A1 (en) * 1993-09-17 1996-07-10 PHARMACIA & UPJOHN COMPANY Substituted tetronic acids useful for treating hiv and other retroviruses
FI962019A7 (fi) * 1993-11-19 1996-05-20 Parke Davis & Co Pyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina ainein a
DE69433705T2 (de) * 1993-11-19 2005-03-10 Parke, Davis & Company 5,6-Dihydropyronderivate als Proteaseinhibitoren und Antiviralmittel
CA2176044A1 (en) * 1993-11-19 1995-05-26 Elizabeth Lunney Pyrone derivatives as protease inhibitors and antiviral agents
SK283240B6 (sk) * 1993-11-19 2003-04-01 Parke, Davis & Company 5,6-Dihydropyrónové deriváty ako inhibítory proteázy a protivírusové činidlá a farmaceutická kompozícia obsahujúca tieto deriváty
US6005103A (en) * 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US5789440A (en) * 1993-11-19 1998-08-04 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
JPH11503416A (ja) * 1995-03-20 1999-03-26 ファルマシア・アンド・アップジョン・カンパニー Ｈｉｖおよび他のレトロウイルス病を治療するのに有用な置換テトロン酸
WO1998000173A2 (en) * 1996-07-03 1998-01-08 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
JP4462760B2 (ja) * 1997-09-11 2010-05-12 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー プロテアーゼインヒビターとして有用な４−ヒドロキシ−２−オキソ−ピラン誘導体の製法
WO1999046262A1 (en) 1998-03-12 1999-09-16 Teijin Limited Benzofurylpyrone derivatives
JP3929244B2 (ja) * 1998-12-25 2007-06-13 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する芳香族ヘテロ環誘導体
FI113942B (fi) * 2000-08-18 2004-07-15 Control Ox Oy Kasviperäisten fenolisten yhdisteiden käyttö valmistettaessa klamydiainfektion hoidossa ja ennaltaehkäisyssä käyttökelpoista farmaseuttista valmistetta, terveyteen myönteisesti vaikuttavaa ravintoainekoostumusta tai koostumusta lisättäväksi tällaisiin elintarvikkeisiin
EP1281399A3 (en) * 2001-08-01 2004-02-11 Warner-Lambert Company Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
RU2236852C1 (ru) * 2003-06-23 2004-09-27 Закрытое акционерное общество "ДЕСКО" Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций
CN101693664A (zh) 2003-10-24 2010-04-14 隆萨股份公司 6,6,6-三卤-3,5-二氧代己酸酯的制备方法
HRP20110845T1 (hr) * 2006-06-16 2011-12-31 Pharma Mar Antitumorski dihidropiran-2-onski spojevi
PT2231633E (pt) 2007-12-20 2014-01-20 Pharma Mar Sa Compostos antitumorais
DE102008055916A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Allylalkoholen und ihre Verwendung
DE102008055914A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acroleinen und ihre Verwendung
WO2010051883A1 (de) 2008-11-05 2010-05-14 Clariant International Ltd Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels allylalkoholen/acroleinen und ihre verwendung
DE102008056339A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von mono-aminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
EP2352740B1 (de) 2008-11-07 2014-09-24 Clariant Finance (BVI) Limited Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels acrylsäurederivaten und ihre verwendung
DE102008056341A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
DE102008056342A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
EP2367835B1 (de) 2008-11-11 2013-12-11 Clariant Finance (BVI) Limited Verfahren zur herstellung von mono-allylfunktionalisierten dialkylphosphinsäuren, deren salze und ester mit allylischen verbindungen und ihre verwendung
DE102008060036A1 (de) * 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060035A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de) * 2008-12-04 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
KR101697948B1 (ko) 2008-12-18 2017-01-19 클라리언트 파이넌스 (비브이아이)리미티드 아세틸렌을 사용하는 에틸렌디알킬포스핀산, 에틸렌디알킬포스핀산 에스테르 및 에틸렌디알킬포스핀산 염의 제조방법 및 이의 용도
DE102008063627A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
DE102008063642A1 (de) * 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
DE102008063668A1 (de) 2008-12-18 2010-07-01 Clariant International Limited Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
DE102008064012A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Halogenfreie Addukte von Alkylphosphonigsäurederivaten und diesterbildenden Olefinen, halogenfreie Verfahren zu deren Herstellung und ihre Verwendung
DE102008064003A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
US20120202814A1 (en) * 2009-10-02 2012-08-09 Università Degli Studi Di Siena Compounds with ddx3 inhibitory activity and uses thereof
CN102690275A (zh) * 2011-03-25 2012-09-26 中国人民解放军第二军医大学 四氢呋喃并[3,4-c]吡喃酮类化合物及其制备方法和用途
CN103044375B (zh) * 2012-12-02 2015-08-12 大理学院 一种二氢吡喃酮化合物及其制备方法和药物用途
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
CN114835694B (zh) * 2022-05-25 2024-06-21 中国科学技术大学 一种在水介质中合成手性3，4-二氢-2h-吡喃类化合物的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1276654A (fr) * 1958-10-01 1961-11-24 Nouveaux dérivés de l'hydroxy-4-alpha-2-pyrone
FR1276645A (fr) * 1959-12-28 1961-11-17 Wild Heerbrugg Ag Objectif de microscope
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
WO1989007939A2 (en) * 1988-03-01 1989-09-08 The Upjohn Company Coumarins to inhibit reverse transcriptase in humans
WO1991004663A1 (en) * 1989-09-26 1991-04-18 The Regents Of The University Of California 6-amino-1,2-benzopyrones useful for treatment of viral diseases
WO1991006561A1 (en) * 1989-10-27 1991-05-16 The Upjohn Company Method for treating hiv and other retroviruses and compounds useful therefor
DE4103904C2 (de) * 1991-02-08 1995-06-14 Analyticon Ges Fuer Chemische Neue Arzneimittel aus Gamma-Pyronen, Gamma-Pyridonen sowie Gamma-Thiopyronen

Also Published As

Publication number Publication date
CA2145661C (en) 2008-04-01
PL178653B1 (pl) 2000-05-31
BR9307451A (pt) 1999-08-31
CN1040321C (zh) 1998-10-21
PL308998A1 (en) 1995-09-18
RU95112465A (ru) 1997-03-20
FI952302A0 (fi) 1995-05-11
DE69332292T2 (de) 2003-05-28
ZA938019B (en) 1995-04-28
KR100314975B1 (ko) 2002-02-28
SK285001B6 (sk) 2006-04-06
HU228126B1 (en) 2012-12-28
EP0668860B1 (en) 2002-09-11
RU2134691C1 (ru) 1999-08-20
EP1203770B1 (en) 2005-03-09
CZ107895A3 (en) 1995-12-13
IL107556A0 (en) 1994-02-27
PT668860E (pt) 2003-01-31
CA2145661A1 (en) 1994-05-26
JPH08503216A (ja) 1996-04-09
MY119031A (en) 2005-03-31
JP3583127B2 (ja) 2004-10-27
NO951899D0 (no) 1995-05-12
HUT71558A (en) 1995-12-28
CN1090279A (zh) 1994-08-03
DK0668860T3 (da) 2003-01-20
EP1203770A1 (en) 2002-05-08
IL107556A (en) 2001-08-08
NZ258013A (en) 1997-02-24
CZ291853B6 (cs) 2003-06-18
GEP20094660B (en) 2009-03-25
LV13088B (en) 2004-01-20
DE69333771T2 (de) 2006-04-06
WO1994011361A1 (en) 1994-05-26
ATE223910T1 (de) 2002-09-15
ES2182837T3 (es) 2003-03-16
FI952302L (fi) 1995-05-11
DE69333771D1 (de) 2005-04-14
SK61695A3 (en) 1995-10-11
DE69332292D1 (de) 2002-10-17
HU9501411D0 (en) 1995-06-28
AU5549394A (en) 1994-06-08
NO319914B1 (no) 2005-10-03
ES2237624T3 (es) 2005-08-01
PT1203770E (pt) 2005-05-31
AU687368B2 (en) 1998-02-26
NO951899L (no) 1995-07-12
FI120399B (fi) 2009-10-15
ATE290531T1 (de) 2005-03-15
EP0668860A1 (en) 1995-08-30
KR950704290A (ko) 1995-11-17

Similar Documents

Publication Publication Date Title
DK1203770T3 (da) Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme
DE69415824D1 (de) 16-substituierte-4-aza-androstan-5-alpha-reduktase-isozym-i-inhibitoren
DK1021223T3 (da) Elektromagnetisk strålingsbehandling
CA2163904A1 (en) Use of Indolocarbazole Derivatives to Treat a Pathological Condition of the Prostate
FI931765A7 (fi) Steroidijohdannaisia eturauhasen liikakasvun käsittelyyn, niiden valmistus ja käytöt
NO991192L (no) Middel for behandling av prostatahypertrofi og prostatakreft
DK0701546T3 (da) Aromatiske acetylchlolinesteraseinhibitorer
ATE178795T1 (de) 7-substituierte-4-aza-steroid-derivate als 5- alpha-reductase-hemmer
ATE206622T1 (de) Verwendung von bismuth-213 konjugate zur behandlung von mikrometastasen
NO951718L (no) Fremgangsmåter og sammensetninger av (+)doksazosin for behandling av godartet hyperplasi og aterosklerose
DE69519728D1 (de) 17 beta-aryl-4-aza-steroidderivate
KR950700746A (ko) 양성 전립선 비대를 치료하는 조성물 및 방법(Compositions and Methods For Treating Benign Prostatic Hypertrophy)
NO975838L (no) Melatoninagonister for behandling av godartet prostatisk hyperplasi
ZA922010B (en) Improved method of treatment for benign prostatic hyperplasia
ITMI922801A0 (it) Antiandroigeni per la terapia dell'ipertrofia prostatica dell'irsutismo dell'acne e della seborrea e relativi procedimenti di preparazione
BR8906008A (pt) Aparelho para dilatacao da uretra prostatica e processo para tratamento de hiperplasia prostatica benigna
NO892044D0 (no) Fremgangsmaate og anlegg for behandling av borekaks.
UA34374A (uk) Спосіб лікування виразкової хвороби дванадцятипалої кишки
MX9710075A (es) Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna.